Regulus Announces New Publication Showing Potential Therapeutic Benefit of Targeting microRNA-21 in Fibrosis

February 16, 2012

-New study published in Science Translational Medicine demonstrates microRNA-21 contributes to fibrogenesis in the kidney -Regulus, in partnership with Sanofi, developing novel anti-fibrotic therapies targeting microRNAs B.N. Chau et al. “MicroRNA-21 Promotes Fibrosis of the Kidney by Silencing Metabolic Pathways” Sci Transl Med 15 February 2012: Vol. 4, Issue 121, p. 121ra18 Sci. Transl. Med. [...]

Read the full article →

miR-375 a potential prognostic marker of head and neck cancers

January 25, 2012

Low-Level Expression of miR-375 Correlates with Poor Outcome and Metastasis While Altering the Invasive Properties of Head and Neck Squamous Cell Carcinomas. Researchers at Department of Pathology, Albert Einstein College of Medicine used global miRNA expression profiling of head and neck squamous cell carcinoma (HNSCC) samples and adjacent normal tissue to rank those miRNAs that [...]

Read the full article →

miRdSNP: a database of disease-associated SNPs and microRNA target sites on 3′UTRs of human genes

January 25, 2012

Single nucleotide polymorphisms (SNPs) can lead to the susceptibility and onset of diseases through their effects on gene expression at the posttranscriptional level. Recent findings indicate that SNPs could create, destroy, or modify the efficiency of miRNA binding to the 3′UTR of a gene, resulting in gene dysregulation. With the rapidly growing number of published [...]

Read the full article →

Marina Biotech Receives Notice of Acceptance for Patent Broadly Covering Its Unlocked Nucleobase Analog (UNA) Technology

January 23, 2012

Patent Protects Use of UNAs in Multiple Nucleic Acid Constructs Including siRNAs, microRNA Mimics, Antagomirs and Single-Stranded Constructs BOTHELL, WA–(Marketwire – Jan 23, 2012) – Marina Biotech, Inc. (NASDAQ: MRNAD), a leading oligonucleotide-based drug discovery and development company today announced that the Intellectual Property Office of New Zealand (IPONZ) has issued a Notice of Acceptance [...]

Read the full article →

Rosetta Green Has Successfully Improved Plant Growth Under Intermittent Irrigation With Seawater

January 10, 2012

The experiment tested a specific microRNA gene that was identified in corn and soybean, and confirmed the potential to develop plants capable of withstanding intermittent irrigation with seawater and growth in high salinity soils During the experiment, plants were intermittently irrigated with salt water with three times the salinity level of seawater Rosetta Green has [...]

Read the full article →

Silence Therapeutics Signs Collaboration with miRagen Therapeutics to Evaluate Delivery of Novel microRNA-based Therapeutics

January 9, 2012

LONDON, January 9, 2012/PRNewswire-FirstCall/ – – Third collaboration to investigate the potential application of Silence’s proprietary RNAi delivery technologies in the development of novel microRNA-based therapeutics Silence Therapeutics plc (AIM: SLN) (“Silence”), a leading RNA interference (RNAi) therapeutics company, announces that it has signed an agreement with miRagen Therapeutics, Inc. (“miRagen”), to assess the delivery [...]

Read the full article →

RNA Interference – Video Animation

January 6, 2012

This is an amazing video animation from Nature Reviews Genetics! This animation introduces the principles of RNAi involving small interfering RNAs (siRNAs) and microRNAs (miRNAs). It takes you on an audio-visual journey through the steps of gene expression and shows you an up-to-date view of how RNAi can silence specific mRNAs in the cytoplasm. There [...]

Read the full article →

Hepatitis C virus hijacks liver microRNA

January 3, 2012

Stabilization of hepatitis C virus RNA by an Ago2–miR-122 complex MicroRNAs regulate eukaryotic gene expression by binding to regions of imperfect complementarity in mRNAs, typically in the 3′ UTR, recruiting an Argonaute (Ago) protein complex that usually results in translational repression or destabilization of the target RNA. The translation and decay of mRNAs are closely [...]

Read the full article →

Regulus Therapeutics Initiates an Orphan and Rare Disease microRNA Therapeutic Effort in Brain Cancer

December 12, 2011

-Regulus, Accelerate Brain Cancer Cure (ABC2) and Samsung Medical Center to Advance microRNA Therapeutics for Glioblastoma – LA JOLLA, Calif., Dec. 12, 2011 /PRNewswire/ – Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced the initiation of a new discovery effort in microRNA therapeutics for the treatment [...]

Read the full article →

Rosetta Genomics Announces New York State Approval for miRview mets²

December 9, 2011

Proprietary microRNA Diagnostic for Identification of Cancer of Unknown Primary Now Available in All 50 U.S. States PHILADELPHIA, PA and REHOVOT, ISRAEL–(Marketwire – Dec 9, 2011) – Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announced that the New York State Department of Health has approved miRview® mets² for [...]

Read the full article →

← Previous Entries

Next Entries →